CorMedix Inc. (CRMD) P/E Ratio History
UndervaluedTrading at 3.8x vs 5Y avg 6.4x · 60th percentile · Below historical baseline · Data 2023–2026
Loading P/E history...
P/E Ratio Analysis
As of September 22, 2026, CorMedix Inc. (CRMD) trades at a price-to-earnings ratio of 3.8x, with a stock price of $7.77 and trailing twelve-month earnings per share of $2.02.
The current P/E is 41% below its 5-year average of 6.4x. Over the past five years, CRMD's P/E has ranged from a low of 0.4x to a high of 27.6x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.8x, CRMD trades at a 84% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 175.0x.
Relative to the broader market, CRMD trades at a notable discount to the S&P 500 median P/E of 25.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRMD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRMD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CRMD P/E vs Peers
Vaccines and Infectious Disease peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $13B | 43.5 | 1.89Best | -25% | |
| $5B | 11.5Lowest | - | +68% | |
| $948M | 150.7 | - | +107%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CRMD Historical P/E Data (2023–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $7.85 | $2.13 | 3.7x | -42% |
| FY2026 Q1 | - | $6.79 | $2.12 | 3.2x | -50% |
| FY2025 Q4 | Dec 31 2025 | $11.63 | $1.99 | 5.8x | -9% |
| FY2025 Q3 | - | $11.63 | $2.06 | 5.6x | -12% |
| FY2025 Q2 | Jun 30 2025 | $12.32 | $0.75 | 16.4x | +155% |
| FY2025 Q1 | Mar 31 2025 | $6.16 | $0.22 | 27.6x | +331% |
| FY2023 Q4 | Dec 31 2023 | $3.76 | $9.09 | 0.4x | -94% |
| FY2023 Q3 | Sep 30 2023 | $3.70 | $9.16 | 0.4x | -94% |
| FY2023 Q2 | Jun 30 2023 | $3.97 | $9.17 | 0.4x | -93% |
| FY2023 Q1 | Mar 31 2023 | $4.14 | $9.23 | 0.4x | -93% |
Average P/E for displayed period: 6.4x
CRMD Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
3+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRMD — Frequently Asked Questions
Quick answers to the most common questions about buying CRMD stock.
What is CRMD's P/E ratio?
CorMedix Inc. (CRMD) trailing twelve-month P/E ratio is 3.8x, based on TTM diluted EPS of $2.02. The 5-year average P/E is 6.4x and the historical range spans 0.4x to 27.6x.
Is CRMD stock overvalued or undervalued?
CRMD trades at 3.8x P/E, below its 5-year average of 6.4x. At the 60th percentile of its historical range (0.4x–27.6x), the stock is priced at a discount to its own history.
Is CRMD stock expensive?
No, CRMD is not expensive on a historical basis. The current P/E of 3.8x is below the 5-year average of 6.4x and sits at the 60th percentile of its valuation range.
What is CRMD's historical P/E range?
Over the past 5 years, CRMD's P/E ratio has ranged from 0.4x to 27.6x, with a median of 3.7x and an average of 6.4x. The current P/E of 3.8x places the stock at the 60th percentile of this range. Full historical data spans 2023–2026.
How does CRMD's P/E compare to the S&P 500?
CRMD trades at 3.8x P/E versus the S&P 500 median of 25.5x. The 85% discount to the market suggests lower growth expectations or perceived higher risk.
How does CRMD's valuation compare to Healthcare peers?
CorMedix Inc. P/E of 3.8x compares to the Healthcare sector median of 23.8x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CRMD's PEG ratio?
CRMD PEG ratio is N/A, based on a P/E of 3.8x and EPS growth of 780.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CRMD's earnings yield?
CRMD earnings yield is 26.25%, the inverse of its 3.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.